Business News • PR NewsWire • Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

TARRYTOWN, N.Y. and PARIS, Dec. 8, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Dupixent® (dupilumab) for the treatment of...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-marketing-authorization-application-for-dupixent-d...

Releted News by prnewswire

La rivoluzione digitale ha cambiato le regole del mercato assicurativo

Global Sources appoints Craig Pepples as CEO

El último chaleco anti-balas protege además de los tiros a quemarropa y TASER

Vegas On The Potomac: MGM National Harbor Opens Today Overlooking Nation's Capital